JHS Svendgaard Laboratories Reports Negative Financial Results for Q4 2023

Feb 14 2024 11:15 PM IST
share
Share Via
JHS Svendgaard Laboratories, a microcap company in the FMCG industry, reported a negative financial performance for the quarter ending December 2023. The company's net sales and profit after tax have declined, while non-operating income is high. Investors should carefully evaluate these factors before making any investment decisions.

JHS Svendgaard Laboratories, a microcap company in the FMCG industry, recently announced its financial results for the quarter ending December 2023. The results, declared on February 14, 2024, have received a 'Strong Sell' call from MarketsMOJO.

According to the financials, JHS Svendgaard Laboratories has seen a negative performance in the quarter, with a score of -11 compared to 4 in the previous 3 months. However, there are some positive aspects to the company's performance.

One of the highlights is the earnings per share (EPS) for the quarter, which is the highest in the last five quarters at Rs 0.00. This shows an increase in profitability and the company's ability to generate higher earnings for its shareholders.

On the other hand, there are some areas of concern for JHS Svendgaard Laboratories. The net sales for the quarter have fallen by -35.6% compared to the average net sales of the previous four quarters. This indicates a negative trend in the company's sales in the near term.

Moreover, the net sales for the quarter are also the lowest in the last five quarters, with a decline in each quarter. This further highlights the negative trend in the company's sales.

In terms of profit after tax (PAT), JHS Svendgaard Laboratories has seen a growth of -32.87% year on year, with a PAT of Rs -0.72 cr for the half-yearly period. This indicates a negative trend in the near term for the company's PAT.

Another concerning aspect is the non-operating income for the quarter, which is 425.45% of the profit before tax (PBT). This suggests that the company's income from non-business activities is high, which may not be a sustainable business model.

Overall, JHS Svendgaard Laboratories has seen a negative financial performance in the quarter ending December 2023. While there are some positive aspects, such as the EPS, the company's sales and PAT trends are a cause for concern. Investors should carefully consider these factors before making any investment decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News